PBYI Surges 30% in 3 Months: How Should You Play the Stock?

Puma Biotechnology (PBYI) shares surged 29.6% over the past three months, significantly outperforming broader markets, driven by better-than-expected results and improving sales of its sole marketed product, Nerlynx. Nerlynx sales grew 9% year-over-year to $92.3 million in H1 2025, with full-year sales projected at $192-$198 million. The company anticipates initial Phase II data for its pipeline candidate alisertib in lung and breast cancer in Q4 2025, which is critical for diversifying revenue away from Nerlynx and addressing competitive pressures in its markets. While the stock's performance is positive, its heavy reliance on Nerlynx and intense competition remain key risks, making successful alisertib data readouts a crucial catalyst.

Analysis

Puma Biotechnology (PBYI) has demonstrated significant stock price momentum, rallying 29.6% in the last three months and substantially outperforming its industry's 3.9% rise. This performance is underpinned by improving fundamentals for its sole commercial product, Nerlynx, which saw sales grow 9% year-over-year to $92.3 million in the first half of 2025. Management's full-year sales guidance of $192-$198 million suggests continued demand-driven growth. However, this positive operational trend is counterbalanced by significant concentration risk, as the company is entirely dependent on Nerlynx for revenue. The key upcoming catalyst is the initial Phase II data for its pipeline candidate, alisertib, expected in Q4 2025, which represents a critical opportunity to diversify. Despite the stock trading at a P/S ratio of 0.94, a discount to the industry's 2.13, it faces intense competition from established oncology players, and any pipeline setbacks could severely impact its growth prospects, justifying the market's cautious sentiment.

Key Decisions for Investors

• Investors should treat the upcoming Phase II data for alisertib in Q4 2025 as a major binary event, as a positive readout is critical to de-risk the company's single-product dependency and justify a higher valuation.
• Given the stock's recent run-up, prospective investors should weigh the attractive P/S valuation against the significant concentration risk and intense competition, potentially adopting a wait-and-see approach pending the pipeline data.
• Current shareholders could consider holding their positions to capitalize on the existing Nerlynx sales momentum and positive EPS estimate revisions for 2026, while remaining aware of the high-stakes nature of the upcoming clinical trial results.